CIK 0001783183 · Non-accelerated filer<br>Smaller reporting company
Phathom Pharmaceuticals, Inc.
Sign in to watch- Ticker
- PHAT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 824151574
- Phone
- (877) 742-8466
- Business address
- 100 CAMPUS DRIVE,, SUITE 102, FLORHAM PARK, NJ, 07932
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-29 | KARBE FRANK Director | Grant or award | +25,000 | $10.16 | $254K | 44,500 |
| 2024-05-23 | Topper James N Director | Grant or award | +10,500 | 32,096 | ||
| 2024-05-23 | Topper James N Director | Grant or award · Stock Option (Right to Buy) | −17,500 | 17,500 | ||
| 2024-05-23 | Parikh Asit Director | Grant or award | +10,500 | 65,500 | ||
| 2024-05-23 | Parikh Asit Director | Grant or award · Stock Option (Right to Buy) | −17,500 | 17,500 | ||
| 2024-05-23 | COLA MICHAEL F Director | Grant or award | +10,500 | 29,298 | ||
| 2024-05-23 | COLA MICHAEL F Director | Grant or award · Stock Option (Right to Buy) | −17,500 | 17,500 | ||
| 2024-05-23 | FIELDS HEIDI Director | Grant or award | +10,500 | 19,500 | ||
| 2024-05-23 | FIELDS HEIDI Director | Grant or award · Stock Option (Right to Buy) | −17,500 | 17,500 | ||
| 2024-05-23 | KARBE FRANK Director | Grant or award | +10,500 | 19,500 | ||
| 2024-05-23 | KARBE FRANK Director | Grant or award · Stock Option (Right to Buy) | −17,500 | 17,500 | ||
| 2024-05-23 | Stenhouse Mark Director | Grant or award | +10,500 | 19,500 | ||
| 2024-05-23 | Stenhouse Mark Director | Grant or award · Stock Option (Right to Buy) | −17,500 | 17,500 | ||
| 2024-05-23 | Socks David A Director | Grant or award | +10,500 | 19,500 | ||
| 2024-05-23 | Socks David A Director | Grant or award · Stock Option (Right to Buy) | −17,500 | 17,500 | ||
| 2024-04-08 | Henderson Molly CFO and CBO | Sale | −3,435 | $11.10 | $38K | 95,263 |
| 2024-03-22 | Curran Terrie President and Chief Executive | Sale | −16,851 | $9.11 | $154K | 410,784 |
| 2024-01-24 | TAKEDA PHARMACEUTICAL CO LTD 10% owner | Sale | −3,703,703 | $8.10 | $30.0M | 3,755,583 |
| 2024-01-19 | Henderson Molly CFO and CBO | Sale | −6,307 | $7.75 | $49K | 98,698 |
| 2024-01-18 | Henderson Molly CFO and CBO | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 |
Page 6 of 19 · 379 trades